SelenBio, Inc.

Antibacterial Technology

Company Information

Website:

https://www.selenbio.com/

Sector:

Biotechnology

Location:

Austin, TX

SelenBio is a biotech company that’s developed a proprietary antibacterial technology.

Its technology prevents the formation of biofilm, the primary source of harmful bacteria in the body.

Delivered as an FDA-cleared compound, this company’s technology can be integrated into products in the medical, dental, industrial, and consumer goods industries, killing harmful bacteria for the life of the product.

SelenBio is led by an experienced team:

CEO Kenny Gallagher has spent 30 years working with startups, and led a previous biotech company to an acquisition by Henry Schein (NASDAQ: HSIC), a healthcare company with a $9 billion market cap. President Karl Doenges has extensive experience in the biotech industry, with a focus on product commercialization.

The popular image of bacteria depicts single cells floating around, releasing toxins and damaging the body.

In truth, most bacteria don’t exist in this form. Rather, they manifest in central communities called “biofilms.”

Within a biofilm, one or more types of bacteria share nutrients and DNA in order to evade the body’s immune system. Because it requires less oxygen and fewer nutrients, biofilm is considered a “hostile community” for most antibiotics. In addition, it often forms a physical barrier that keeps most immune cells from reaching, or even detecting, the bacteria.

If left untreated in the body, bacteria can reproduce quickly and cause illness. The risk of severe infection or disease is especially high around implanted medical devices like hernia meshes, orthopedic implants, catheters, and vascular grafts.

Meanwhile, current silver- and copper-based antimicrobials used for treatment of bacterial growth are costly and carry harmful side effects. As a result, there has been an increased need for new antibacterial agents to fight biofilms.

Adding to this need are recent changes in healthcare reimbursement policy. These changes have shifted the cost of implant infections back to the original service provider as a “preventable infection.” In fact, according to a 2018 report from Fierce Healthcare, antibiotic resistance adds more than $1,000 to the cost of treatment for a single patient. These costs add up to more than $2 billion a year in the U.S. alone.

SelenBio can help reduce these costs with its antibacterial compound called SELDOX.

In a nutshell, SELDOX works by generating superoxide radicals which destroy bacteria on contact. This disrupts the colonization and prevents the formation of biofilm.

Unlike other antibacterial solutions, SELEDOX offers the following features:

It’s Effective: SELDOX never stops fighting bacteria, and provides protection throughout the life of the product. The compound has achieved 99.9% effectiveness in killing numerous bacteria, fungus, and viruses.

It’s “Non-Leaching”: Other antimicrobials like silver- and copper-based solutions leach into the body. SELDOX, in contrast, remains bound to the product and doesn’t affect a patient’s bloodstream.

It’s Safe: SELDOX is non-toxic and is safe to use on products inserted into the body.

It’s Cost-Effective: SELDOX is more affordable than silver- or copper-based antimicrobials.

As mentioned, SelenBio’s antibacterial technology can treat products used in several different industries, including medical and dental devices, industrial equipment, and consumer goods.

The company has joint-development projects underway in the medical device industry (specifically, treating wound care bandages and silicone used in manufacturing urinary catheters); the commercial paint industry to prevent bacterial growth in hospitals, nursing homes, and schools; and consumer products like water bottles and athletic clothing.

To generate revenue, SelenBio receives licensing fees from companies looking to use SELDOX for its products, as well as royalty payments from the sale of these products.

Team Background

Karl Doenges - President

Karl has extensive experience in the biotech industry, focusing on product commercialization.

Before SelenBio, he was an advisor for Cranberry Capital, a venture capital firm. Prior to that, he was Vice President of Marketing for Gradiant Corporation, a water treatment plant operation.

Earlier, he served as President at Clean Fuel Distribution, an energy company.

Karl is a member of the State Bar of Texas, and served on the U.S. District Export Council for the U.S. Department of Commerce for more than 10 years.

He earned a Bachelor’s degree from the University of Texas, and a J.D. and MBA from Texas Tech University.

Kenny Gallagher - CEO

Kenny has more than 30 years of startup experience, including time as CEO of a company working with selenium technology, SelenBio’s key material.

He began his career starting Mini-Phone, a telecommunications company that he later sold to a larger competitor.

From there, he served as President for ClassOne, a dental and orthodontic supply company. While there, he helped the company develop its biotech antibacterial technology, and led the sale of the business to Henry Schein (NASDAQ: HSIC), a healthcare products distributor with a $9 billion market cap.

Kenny earned a Bachelor’s degree in Accounting from Nicholls State University.

Matt Belsole - Director of Business Development

Matt has 15 years of experience in sales management and strategy for healthcare and medical device products.

Before joining the team at SelenBio, he worked alongside CEO Kenny Gallagher at ClassOne for seven years.

Co-Investors

Raising
$1.07 million
Committed
$108.708K (10%)
Current Valuation
$19.71 million
Min. Investment
$100
Deal Type
Title III
(For all investors)
Offering Type
Equity
Finance History
Notable Investors
Learn more on Netcapital